The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index, and 1 are not checked yet.
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype
Open accessAbstract
Although a wide variety of mechanisms take part in the secondary injury phase of spinal cord injury (SCI), inflammation is the most important factor implicated in the sequelae after SCI. Being central to the inflammation reaction, macrophages and their polarization are a topic that has garnered wide interest in the studies of SCI secondary injury. The glucagon-like peptide 1 (GLP-1) receptor agonist exenatide has been shown to enhance the endoplasmic reticulum stress response and improve motor function recovery after spinal cord injury (SCI). Since exenatide has also been reported to induce the production of M2 cells in models of cerebral infarction and neurodegenerative diseases, this study was conducted to examine the effects of exenatide administration on the inflammation process that ensues after spinal cord injury. In a rat contusion model of spinal cord injury, the exenatide group received a subcutaneous injection of 10 μg exenatide immediately after injury while those in the control group received 1 mL of phosphate-buffered saline. Quantitative RT-PCR and immunohistochemical staining were used to evaluate the effects of exenatide administration on the macrophages infiltrating the injured spinal cord, especially with regard to macrophage M1 and M2 profiles. The changes in hind limb motor function were assessed based on Basso, Beattie, Bresnahan locomotor rating scale (BBB scale) scores. The improvement in BBB scale scores was significantly higher in the exenatide group from day 7 after injury and onwards. Quantitative RT-PCR revealed an increase in the expression of M2 markers and anti-inflammatory interleukins in the exenatide group that was accompanied by a decrease in the expression of M1 markers and inflammatory cytokines. Immunohistochemical staining showed no significant difference in M1 macrophage numbers between the two groups, but a significantly higher number of M2 macrophages was observed in the exenatide group on day 3 after injury. Our findings suggest that exenatide administration promoted the number of M2-phenotype macrophages after SCI, which may have led to the observed improvement in hind limb motor function in a rat model of SCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with GLP-1RAs can effectively mitigate chondrocyte apoptosis caused by endoplasmic reticulum stress and alleviate the associated inflammatory response.277–280”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [280]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
A Sensitive and Reliable Locomotor Rating Scale for Open Field Testing in Rats
BASSO, D. M., BEATTIE, M. S., & BRESNAHAN, J. C. (1995) · Journal of Neurotrauma · doi:10.1089/neu.1995.12.1 · Cited by 3,963
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“…declines due to chronic nonspecific inflammatory reactions including oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction (Böni-Schnetzler and Meier, 2019), and the anti-inflammatory properties of GLP-1 receptor agonists improve islet cell function (Nauck et al., 2021).”
BackgroundDonnelly, D. J., & Popovich, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.009 · Cited by 995
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade
Oyinbo, C. (2011) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2011-1848 · Cited by 786
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Halabitska, I., Бабинец, Л. С., Oksenych, V., & Kamyshnyi, O. (2024) · Biomedicines · doi:10.3390/biomedicines12081630 · Cited by 60
Advances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
Spezani, R., & Mandarim‐de‐Lacerda, C. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70400 · Cited by 24
Metadata
- Authors
- Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M.
- Affiliations
- Tokai University (JP)
- Corresponding author
- Katoh, Hiroyuki
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2024-02-15
- Volume
- 18
- Pages
- 1342944-1342944
- ISSN
- 1662-453X (ISSN-L)
- PMC
- PMC10902060
- OpenAlex
- W4391838285
- Cited by
- 20
- References
- 93
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 3
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- JSPS
- Topics
- Health Sciences › Medicine › Clinical Neurology › Spinal Cord Injury Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Keywords
- exenatide, spinal cord injury, macrophage polarization, M2 macrophages, M1 macrophages, GLP-1 receptor agonists, neuroinflammation, secondary injury, bruising, anti-inflammatory cytokines, endoplasmic reticulum stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype. https://app.cochat.ai/papers/10.3389/fnins.2024.1342944
- The paper
- Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024). The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2024.1342944
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.